Abstract
INTRODUCTION: Type 2 diabetes mellitus (T2DM), a chronic metabolic disease, affects millions of people worldwide, causes numerous complications, (eg, cardiovascular disease, kidney damage, neuropathy), and is strongly associated with obesity, a primary risk factor for its development and progression. In this paper, we presented 10-year outcomes of patients with T2DM who underwent metabolic and bariatric surgery (MBS), focusing on factors contributing to T2DM remission. AIM: This 10-year study evaluated MBS efficacy, focusing on T2DM remission predictors and complications. MATERIALS AND METHODS: We analyzed data of 113 patients with T2DM who underwent primary MBS between 2008 and 2014. Individuals with missing / inconsistent data or follow-up shorter than10 years were excluded. Information on surgery and treatment outcomes (described via standardized reporting) was analyzed. RESULTS: The most frequently performed surgery was sleeve gastrectomy (57.5%). Among the analyzed cohort, 10 years postsurgery, 80 patients (70.8%) experienced T2DM remission, 19 (16.8%) T2DM improvement, and 14 (12.4%) had no T2DM-related changes. Median (interquartile range) follow-up was 10.9 (10.4-11.7) years. Multivariable logistic regression showed that T2DM duration of over 10 years was associated with lower likelihood of T2DM remission, whereas the type of surgery was not a significant factor influencing it. However, undergoing one anastomosis gastric bypass (OAGB) tended to increase the probability of T2DM remission. CONCLUSIONS: Although T2DM duration remains a significant predictor of remission, the study suggests a potential trend toward higher remission rates after OAGB, which requires confirmation in larger studies.